Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stem Cells Lenses is an investigational cell therapy product consisting of human umbilical cord mesenchymal stem cells (UCMSCs) loaded onto a contact lens delivery system. Developed by Guangdong ProCapZoom Biosciences, it is designed for the treatment of chronic ocular graft-versus-host disease (coGVHD). The therapeutic approach involves the local administration of UCMSCs to the ocular surface, where they act to modulate donor T cells and prevent them from attacking the recipient's ocular tissues. This localized delivery via a contact lens aims to provide a sustained immunomodulatory effect directly at the site of inflammation, potentially overcoming the limitations of systemic or conventional topical treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Stem Cells Lenses (Guangdong ProCapZoom Biosciences Co., Ltd.).